Daily Derm Times: February 19, 2025

Author(s):

Emma Andrus, Editor

Key Takeaways

At-home radiofrequency and arbutin cream improve melasma and facial aging, showing positive results in melanin, erythema, and dermal thickness.
Sunscreen use among cyclists is insufficient, with women using it more but often failing to reapply correctly.
Zabalafin Hydrogel's FDA clearance marks a novel approach to treating atopic dermatitis by targeting immune and bacterial components.
AI is poised to significantly enhance dermatological diagnostics and treatment, as emphasized by PathAI's co-founder.
Deucravacitinib demonstrates sustained efficacy and safety in psoriasis treatment over a 5-year period, maintaining PASI 75 and PASI 90 responses.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Journal Digest: February 19

This review of the latest dermatologic studies includes insights into scuba diving's dermatological impacts, the impact of COVID-19 and vaccination on dermatological immune-mediated inflammatory diseases, and more.

At-Home Radiofrequency and Arbutin Cream Can Simultaneously Treat Melasma and Facial Aging

Positive results in melanin, erythema, wrinkles, texture, and periorbital dermal thickness were observed during the 8-week study.

Sunscreen Use Among Cyclists Falls Short

A recent study found sunscreen use is higher among women but often not reapplied properly.

FDA Clears Zabalafin Hydrogel’s Investigational New Drug Application for AD

Alphyn’s therapy uniquely treats both the immune system and bacterial components of atopic dermatitis.

VYNE Therapeutics Advances VYN202 with Phase 1b Trial in Moderate to Severe Plaque Psoriasis

VYNE has initiated a phase 1b trial for its oral BD2-selective BET inhibitor.

The Future of AI in Dermatology with Andy Beck, MD, PhD

The co-founder of PathAI and its PathAssist Derm tool believes AI is going to be incredibly valuable for dermatologists and dermatopathologists.

5-Year Study Backs Deucravacitinib’s Safety and Efficacy

The POETYK PSO LTE trial found deucravacitinib effective in sustaining PASI 75 and PASI 90 responses.

Reviewing Complex Cases: Navigating Biologics and JAK Inhibitors

At the Horizons in Advanced Practice meeting, Omar Noor, MD, FAAD, presented a case of a woman aged 25 years who presented with erythematous and scaly patches on her face, neck, and upper trunk.